Aubagio

Drug Overview

In the field of Neurology, providing effective and accessible treatment options for multiple sclerosis (MS) is critical for long-term disease management. Aubagio is a widely prescribed medication belonging to the Pyrimidine Synthesis Inhibitors drug class. It serves as a highly convenient, once-daily oral Disease-Modifying Therapy (DMT) for patients with relapsing forms of MS.

Functioning as a precise Immunotherapy, Aubagio does not broadly wipe out the body’s entire immune system. Instead, it operates as a specialized Targeted Therapy. By slowing down the rapid multiplication of specific immune cells that drive inflammation, it reduces the frequency of MS relapses and slows the accumulation of long-term physical disability.

• Generic Name: Teriflunomide
• US Brand Names: Aubagio
• Route of Administration: Oral (Tablets)
• FDA Approval Status: Fully FDA-approved for the treatment of relapsing forms of multiple sclerosis in adults.

What Is It and How Does It Work? (Mechanism of Action)

Aubagio is an immunomodulatory agent with anti-inflammatory properties. In multiple sclerosis, the body’s activated T-cells and B-cells (white blood cells) cross the blood-brain barrier and mistakenly attack the myelin sheath the protective coating around nerve fibers.

At the molecular level, its mechanism of action involves a unique enzymatic blockade:

• Enzyme Inhibition: Teriflunomide reversibly inhibits dihydroorotate dehydrogenase (DHODH). This specific mitochondrial enzyme is necessary for the de novo (from scratch) synthesis of pyrimidines, which are the building blocks of DNA and RNA.
• Targeting Rapidly Dividing Cells: When T-cells and B-cells become aggressive and activated in MS, they multiply rapidly and rely heavily on this de novo pathway to copy their DNA. By blocking DHODH, Aubagio starves these overactive immune cells of the materials they need to divide, effectively stopping their proliferation.
• Preserving Normal Immunity: Crucially, resting, non-aggressive immune cells do not rely on the de novo pathway. They utilize a different process called the “salvage pathway” to maintain their basic functions. Because Aubagio acts as a Targeted Therapy, it leaves this salvage pathway intact, allowing the patient to maintain a baseline immune defense against standard infections.

FDA-Approved Clinical Indications

Primary Indication

• Relapsing Forms of Multiple Sclerosis (MS): Aubagio is specifically indicated for the treatment of patients with relapsing forms of multiple sclerosis to decrease the frequency of clinical exacerbations and delay physical disability. This includes:
  • Clinically Isolated Syndrome (CIS)
  • Relapsing-Remitting Multiple Sclerosis (RRMS)
  • Active Secondary Progressive Disease

Other Approved Uses

Due to its highly specific mechanism of altering lymphocyte proliferation, teriflunomide has a narrow clinical profile.

• There are no FDA-approved uses for Aubagio in oncology, cardiology, nephrology, or general medicine.

Dosage and Administration Protocols

Dosing for Aubagio is straightforward, consisting of a single daily tablet taken with or without food.

Clinical Protocol Notes

• Hepatic Insufficiency: No dosage adjustment is required for patients with mild to moderate hepatic impairment. However, Aubagio is absolutely contraindicated in patients with severe hepatic impairment due to the risk of life-threatening liver injury.
• Renal Insufficiency: No specific dosage adjustments are required for mild, moderate, or severe renal impairment.
• Long Half-Life: Teriflunomide stays in the bloodstream for up to 2 years after the last dose is taken. This requires specific medical interventions if the drug needs to be cleared quickly for safety or pregnancy reasons.

Clinical Efficacy and Research Results

Clinical trials and extensive long-term data registries (2020-2026) validate Aubagio as a reliable, moderate-efficacy oral therapy:

• Relapse Rate Reduction: Standardized clinical data confirm that patients treated with the 14 mg dose of Aubagio experience an approximate 31% to 36% reduction in annualized relapse rates compared to those on a placebo.
• Disability Progression: Clinical research demonstrates a 31% risk reduction in 12-week confirmed disability progression for patients on the 14 mg dose.
• MRI Biomarker Improvement: Brain MRIs consistently show that Aubagio reduces the total volume of new or enlarging T2 lesions by approximately 67% to 69% and significantly decreases the appearance of active, gadolinium-enhancing T1 lesions (markers of acute inflammation) by up to 80%.

Safety Profile and Side Effects

BLACK BOX WARNING: HEPATOTOXICITY AND EMBRYOFETAL TOXICITY

Aubagio carries severe warnings. It can cause clinically significant and potentially fatal liver injury. It is also severely teratogenic; it can cause major birth defects if used by pregnant women, or if a pregnancy occurs while the drug is still in the body of either the mother or the father.

Common Side Effects (>10%)

• Headache
• Elevated liver enzymes (ALT/AST)
• Alopecia (hair thinning or hair loss, usually stabilizing after a few months)
• Diarrhea and nausea
• Hypophosphatemia (low blood phosphorus levels)

Serious Adverse Events

• Hepatic: Severe drug-induced liver injury and acute liver failure.
• Reproductive: Severe embryofetal toxicity. The drug remains in the blood for up to 2 years after stopping unless rapidly eliminated.
• Neurological: Peripheral neuropathy (nerve damage in the hands and feet causing numbness or burning).
• Dermatological: Severe, potentially fatal skin reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).
• Respiratory: Interstitial lung disease (a severe scarring of the lung tissue).
• Cardiovascular: Clinically significant increases in blood pressure.

Management Strategies

• Accelerated Elimination Procedure: If a patient becomes pregnant, experiences severe liver toxicity, or needs to switch medications rapidly, physicians use an accelerated elimination protocol. This involves administering cholestyramine (or activated charcoal) for 11 days to bind to the drug in the digestive tract and flush it from the body safely in weeks rather than years.
• Hair Loss Management: Alopecia is usually temporary. It typically begins in the first month and resolves or stabilizes by month six without requiring the drug to be stopped.

Connection to Stem Cell and Regenerative Medicine

In the rapidly advancing sphere of Regenerative Medicine for multiple sclerosis, Immunomodulators like Aubagio serve a vital preparatory role. Current research (2025–2026) emphasizes that endogenous myelin repair (remyelination) or the introduction of neural stem cell therapies cannot succeed in a highly inflamed, hostile central nervous system. By utilizing this Targeted Therapy to suppress the proliferation of aggressive T-cells and B-cells, neurologists can create a “permissive microenvironment.” Establishing this stable, low-inflammation baseline is considered a mandatory prerequisite to ensure the survival and functional integration of future cellular therapies aimed at repairing damaged spinal and brain tissue.

Patient Management and Practical Recommendations

Pre-treatment Tests

• Comprehensive Liver Panel: Baseline AST, ALT, and bilirubin levels must be obtained within 6 months prior to starting.
• Pregnancy Test: A confirmed negative pregnancy test is mandatory for women of childbearing potential.
• Complete Blood Count (CBC): To establish baseline white blood cell counts.
• Tuberculosis Screening: A test for latent TB is required, as the drug can cause the infection to become active.
• Blood Pressure: Establishing a baseline reading to monitor for drug-induced hypertension.

Precautions During Treatment

• Routine Liver Monitoring: Liver enzymes (ALT) must be tested at least monthly for the first 6 months of treatment to catch any early signs of liver toxicity.
• Strict Contraception: Both men and women taking Aubagio must use highly effective, reliable birth control during treatment and until an accelerated elimination procedure verifies the drug is out of their system.

“Do’s and Don’ts” List

• DO check your blood pressure regularly at home, as this medication can cause it to rise.
• DO contact your doctor immediately if you develop unexpected numbness or tingling in your hands or feet.
• DON’T get pregnant while taking this medication. If you wish to start a family, speak to your neurologist months in advance to perform the accelerated elimination procedure.
• DON’T ignore signs of liver distress, such as unexplained fatigue, right-sided stomach pain, dark urine, or yellowing of your skin or eyes.

Legal Disclaimer

This guide is intended for educational and informational purposes only and does not replace professional medical advice, diagnosis, or treatment. Multiple sclerosis is a complex, chronic neurological disorder requiring precise medication management and ongoing supervision by a board-certified neurologist or MS specialist. Always consult your healthcare provider before initiating, altering, or stopping any medication regimen.